Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12905680 | 0.87 | NOS2 (0.34) | — | |
| SCHEMBL826512 | 0.82 | GSR (0.45) | SLC7A5 | |
| SCHEMBL15634459 | 0.82 | GSR (0.45) | SLC7A5 | |
| SCHEMBL13861346 | 0.77 | — | — | |
| SCHEMBL231631 | 0.71 | GSR (0.48) | — | |
| SCHEMBL5668298 | 0.71 | GSR (0.48) | — | |
| SCHEMBL10078915 | 0.71 | METAP1 (0.53) | — | |
| SCHEMBL22435220 | 0.71 | METAP1 (0.53) | — | |
| SCHEMBL14189195 | 0.71 | NOS2 (0.32) | — | |
| SCHEMBL826933 | 0.71 | GSR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786578-B2 | Modified relaxin polypeptides and their uses | AMBRX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | AMBRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-9962450-B2 | Method of treating heart failure with modified relaxin polypeptides | AMBRX, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | AMBRX, INC. | 2017-08-10 | — | — | US | disclosed |
| US-9567386-B2 | Therapeutic uses of modified relaxin polypeptides | AMBRX, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9517273-B2 | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids | AMBRX, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9452222-B2 | Nucleic acids encoding modified relaxin polypeptides | AMBRX, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150273075-A1 | THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS | AMBRX, INC. | 2015-10-01 | — | — | US | disclosed |
| US-9074010-B2 | Modified human plasma polypeptide or Fc scaffolds and their uses | AMBRX, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150038679-A1 | Interleukin-3 Polypeptide Conjugates and Their Uses | AMBRX, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8846876-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | Abrx, Inc. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140194357-A1 | Modified Relaxin Polypeptides and Their Uses | AMBRX, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130237481-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | AMBRX, INC. | 2013-09-12 | — | — | US | disclosed |
| US-8383365-B2 | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives | AMBRX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130030160-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120190827-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | AMBRX, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7939496-B2 | Linked to polyoxyethylene glycol via oximination; improved half-life | AMBRX, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | AMBRX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150273075-A1 | THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES COMPRISING NON-NATURALLY OCCURRING AMINO ACIDS | FGF2, FGF1, HDGF | SLC7A5 1252/4885 |
| US-20230226152-A1 | INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF | IL2, IL2RA, TAP2 | SLC7A5 2199/4885 |
| US-20110172401-A1 | Modified FGF-21 Polypeptides and Their Uses | FGF2, FGF1, FGF23 | SLC7A5 3324/4885 |
| US-20150038679-A1 | Interleukin-3 Polypeptide Conjugates and Their Uses | IL23R, IL2RA, IL2 | SLC7A5 775/4885 |
| US-20110015345-A1 | Modified FGF-23 Polypeptides and Their Uses | FGF23, FGF2, FGF1 | SLC7A5 3489/4885 |
| US-20130237481-A1 | MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES | RXFP1, RXFP2, RXFP3 | SLC7A5 2122/4885 |
| US-20170035897-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | SLC7A5 4040/4885 |
| US-20170226178-A1 | THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES | RXFP1, RXFP2, RXFP3 | SLC7A5 2185/4885 |
| US-20140194357-A1 | Modified Relaxin Polypeptides and Their Uses | RXFP1, RXFP2, RXFP4 | SLC7A5 4040/4885 |
| US-20120190827-A1 | Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses | FGB, FCGR3B, FCGR2A | SLC7A5 3949/4885 |
| US-20130030160-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | PTMS, DAO, DNPEP | SLC7A5 384/4885 |
| US-11786578-B2 | Modified relaxin polypeptides and their uses | RXFP1, RXFP2, RXFP3 | SLC7A5 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.